Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

2.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
3.

[Neuroimmunology and rheumatology: overlap and differential diagnoses].

Trebst C, Kümpfel T.

Nervenarzt. 2018 Oct;89(10):1095-1105. doi: 10.1007/s00115-018-0597-y. Review. German.

PMID:
30215132
4.

Varicella zoster virus infections in neurological patients: a clinical study.

Skripuletz T, Pars K, Schulte A, Schwenkenbecher P, Yildiz Ö, Ganzenmueller T, Kuhn M, Spreer A, Wurster U, Pul R, Stangel M, Sühs KW, Trebst C.

BMC Infect Dis. 2018 May 25;18(1):238. doi: 10.1186/s12879-018-3137-2.

5.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

6.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

7.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

8.

Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization.

Schwenkenbecher P, Pul R, Wurster U, Conzen J, Pars K, Hartmann H, Sühs KW, Sedlacek L, Stangel M, Trebst C, Skripuletz T.

BMC Infect Dis. 2017 Jan 21;17(1):90. doi: 10.1186/s12879-016-2112-z.

9.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.

Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Nov 1;13(1):281.

10.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 27;13(1):280.

11.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 26;13(1):279.

12.

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.

Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke KD, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K; NEMOS (Neuromyelitis Optica Study Group).

Mult Scler. 2017 Jul;23(8):1092-1103. doi: 10.1177/1352458516671203. Epub 2016 Oct 6.

PMID:
27758954
13.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

14.

Intraspinal cavernous bleeding during early pregnancy.

Pars K, Garde N, Conzen J, Pul R, Dengler R, Stangel M, Skripuletz T, Trebst C.

J Neurol. 2016 Oct;263(10):2127-9. doi: 10.1007/s00415-016-8245-6. Epub 2016 Aug 3. No abstract available.

PMID:
27488862
15.

Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNβ-treated and untreated multiple sclerosis patients.

Pul R, Saadat M, Morbiducci F, Skripuletz T, Pul Ü, Brockmann D, Sühs KW, Schwenkenbecher P, Kahl KG, Pars K, Stangel M, Trebst C.

Exp Ther Med. 2016 Jul;12(1):190-200. Epub 2016 Apr 27.

16.

Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.

Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, Aktas O, Kümpfel T, Krumbholz M, Trebst C, Paul F, Pache F, Obermann M, Zeltner L, Schwab M, Berthele A, Jarius S, Kleiter I; Neuromyelitis Optica Study Group.

J Neurol. 2016 Mar;263(3):575-82. doi: 10.1007/s00415-015-7991-1. Epub 2016 Jan 25.

PMID:
26810718
17.

Neurotropic virus infections as the cause of immediate and delayed neuropathology.

Ludlow M, Kortekaas J, Herden C, Hoffmann B, Tappe D, Trebst C, Griffin DE, Brindle HE, Solomon T, Brown AS, van Riel D, Wolthers KC, Pajkrt D, Wohlsein P, Martina BEE, Baumgärtner W, Verjans GM, Osterhaus ADME.

Acta Neuropathol. 2016 Feb;131(2):159-184. doi: 10.1007/s00401-015-1511-3. Epub 2015 Dec 10. Review.

18.

Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis.

Sühs KW, Wegner F, Skripuletz T, Trebst C, Tayeb SB, Raab P, Stangel M.

Exp Ther Med. 2015 Oct;10(4):1283-1292. Epub 2015 Aug 19.

19.

Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; Neuromyelitis Optica Study Group.

Ann Neurol. 2016 Feb;79(2):206-16. doi: 10.1002/ana.24554. Epub 2015 Nov 26.

PMID:
26537743
20.

Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.

Ahlbrecht J, Martino F, Pul R, Skripuletz T, Sühs KW, Schauerte C, Yildiz Ö, Trebst C, Tasto L, Thum S, Pfanne A, Roesler R, Lauda F, Hecker M, Zettl UK, Tumani H, Thum T, Stangel M.

Mult Scler. 2016 Aug;22(9):1202-14. doi: 10.1177/1352458515613641. Epub 2015 Oct 22.

PMID:
26493127
21.

CSF Levels of Angiopoietin-2 Do Not Differ between Patients with CSF Fluid Leakage Syndrome and Controls.

Pul R, Yildiz Ö, Morbiducci F, Skripuletz T, Schwenkenbecher P, Stangel M, Götz F, Berding G, Trebst C, Donnerstag F.

Dis Markers. 2015;2015:343818. doi: 10.1155/2015/343818. Epub 2015 Sep 10.

22.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
23.

Effect of FTY720-phosphate on the expression of inflammation-associated molecules in astrocytes in vitro.

Janssen S, Schlegel C, Gudi V, Prajeeth CK, Skripuletz T, Trebst C, Stangel M.

Mol Med Rep. 2015 Oct;12(4):6171-7. doi: 10.3892/mmr.2015.4120. Epub 2015 Jul 27.

PMID:
26239526
24.

Importance of follow-up cerebrospinal fluid analysis in cryptococcal meningoencephalitis.

Skripuletz T, Schwenkenbecher P, Pars K, Stoll M, Conzen J, Bolat S, Pul R, Vonberg RP, Sedlacek L, Wurster U, Stangel M, Trebst C.

Dis Markers. 2014;2014:162576. doi: 10.1155/2014/162576. Epub 2014 Oct 13.

25.

A pivotal role of nonmuscle myosin II during microglial activation.

Janßen S, Gudi V, Prajeeth CK, Singh V, Stahl K, Heckers S, Skripuletz T, Pul R, Trebst C, Tsiavaliaris G, Stangel M.

Exp Neurol. 2014 Nov;261:666-76. doi: 10.1016/j.expneurol.2014.08.010. Epub 2014 Aug 19.

PMID:
25150163
26.

Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography.

Wegner F, Wilke F, Raab P, Tayeb SB, Boeck AL, Haense C, Trebst C, Voss E, Schrader C, Logemann F, Ahrens J, Leffler A, Rodriguez-Raecke R, Dengler R, Geworski L, Bengel FM, Berding G, Stangel M, Nabavi E.

BMC Neurol. 2014 Jun 20;14:136. doi: 10.1186/1471-2377-14-136.

27.

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group (NEMOS).

J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7. Epub 2013 Nov 23. Review.

28.

Ovarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late.

Boeck AL, Logemann F, Krauß T, Hussein K, Bültmann E, Trebst C, Stangel M.

Case Rep Neurol Med. 2013;2013:843192. doi: 10.1155/2013/843192. Epub 2013 Feb 26.

29.

Blood-cerebrospinal fluid barrier dysfunction in patients with neurological symptoms during the 2011 Northern German E. coli serotype O104:H4 outbreak.

Skripuletz T, Wurster U, Worthmann H, Heeren M, Schuppner R, Trebst C, Kielstein JT, Weissenborn K, Stangel M.

Brain. 2013 Aug;136(Pt 8):e241. doi: 10.1093/brain/aws361. Epub 2013 Feb 11. No abstract available.

PMID:
23404332
30.

Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.

Pul R, Morbiducci F, Škuljec J, Skripuletz T, Singh V, Diederichs U, Garde N, Voss EV, Trebst C, Stangel M.

PLoS One. 2012;7(12):e51867. doi: 10.1371/journal.pone.0051867. Epub 2012 Dec 20.

31.

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl U UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F.

J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.

32.

Visual hallucinations in Charles Bonnet syndrome can be seen in fluorodeoxyglucose-PET.

Garde N, Skripuletz T, Pul R, Berding G, Weissenborn K, Trebst C.

J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):E38-9. doi: 10.1176/jnp.23.4.jnpe38. No abstract available.

PMID:
22231345
33.

Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.

Trebst C, Bronzlik P, Kielstein JT, Schmidt BM, Stangel M.

Blood Purif. 2012;33(1-3):1-6. doi: 10.1159/000332397. Epub 2011 Nov 11.

PMID:
22086365
34.

Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK, Stangel M.

Nat Rev Neurol. 2011 Nov 1;7(12):688-98. doi: 10.1038/nrneurol.2011.176. Review.

PMID:
22045269
35.

Characterisation of microglia during de- and remyelination: can they create a repair promoting environment?

Voss EV, Škuljec J, Gudi V, Skripuletz T, Pul R, Trebst C, Stangel M.

Neurobiol Dis. 2012 Jan;45(1):519-28. doi: 10.1016/j.nbd.2011.09.008. Epub 2011 Sep 21.

PMID:
21971527
36.

Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis.

Voss E, Raab P, Trebst C, Stangel M.

Ther Adv Neurol Disord. 2011 Mar;4(2):123-34. doi: 10.1177/1756285611398702.

37.

Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system.

Skripuletz T, Miller E, Grote L, Gudi V, Pul R, Voss E, Skuljec J, Moharregh-Khiabani D, Trebst C, Stangel M.

Brain Behav Immun. 2011 Nov;25(8):1592-606. doi: 10.1016/j.bbi.2011.05.009. Epub 2011 May 24.

PMID:
21635946
38.

CCL5 induces a pro-inflammatory profile in microglia in vitro.

Skuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharregh-Khiabani D, Kotsiari A, Trebst C, Stangel M.

Cell Immunol. 2011;270(2):164-71. doi: 10.1016/j.cellimm.2011.05.001. Epub 2011 May 26.

PMID:
21620385
39.

[Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Trebst C, Berthele A, Jarius S, Kümpfel T, Schippling S, Wildemann B, Wilke C; Neuromyelitis optica Studiengruppe (NEMOS).

Nervenarzt. 2011 Jun;82(6):768-77. doi: 10.1007/s00115-010-3192-4. German. No abstract available.

PMID:
21174070
40.

Interferon-β treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation.

Kotsiari A, Voss EV, Pul R, Skripuletz T, Ragancokova D, Trebst C, Stangel M.

Neurosci Lett. 2010 Nov 19;485(2):107-11. doi: 10.1016/j.neulet.2010.08.075. Epub 2010 Sep 15.

PMID:
20816724
41.

Beneficial effects of minocycline on cuprizone induced cortical demyelination.

Skripuletz T, Miller E, Moharregh-Khiabani D, Blank A, Pul R, Gudi V, Trebst C, Stangel M.

Neurochem Res. 2010 Sep;35(9):1422-33. doi: 10.1007/s11064-010-0202-7. Epub 2010 Jun 11.

PMID:
20544279
42.

Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis.

Trebst C, Voss E, Skripuletz T, Stangel M.

Curr Med Chem. 2010;17(7):640-50. Review.

PMID:
20088763
43.

Meningeal carcinomatosis from penile squamous cell carcinoma.

Skripuletz T, Pul R, Herrmann J, Bueltmann E, Wurster U, Stangel M, Trebst C.

J Neurooncol. 2010 Jul;98(3):417-9. doi: 10.1007/s11060-009-0087-y. Epub 2009 Dec 15.

PMID:
20013145
44.

Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis.

Bolat S, Berding G, Dengler R, Stangel M, Trebst C.

J Neurol Sci. 2009 Dec 15;287(1-2):257-9. doi: 10.1016/j.jns.2009.08.060. Epub 2009 Sep 15.

PMID:
19755199
45.

Regional differences between grey and white matter in cuprizone induced demyelination.

Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M.

Brain Res. 2009 Aug 4;1283:127-38. doi: 10.1016/j.brainres.2009.06.005. Epub 2009 Jun 12.

PMID:
19524552
46.

Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis.

Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M.

Blood Purif. 2009;28(2):108-15. doi: 10.1159/000224630. Epub 2009 Jun 11.

PMID:
19521072
47.

Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination.

Lindner M, Fokuhl J, Linsmeier F, Trebst C, Stangel M.

Neurosci Lett. 2009 Apr 3;453(2):120-5. doi: 10.1016/j.neulet.2009.02.004. Epub 2009 Feb 10.

PMID:
19356606
48.

Demyelination of the hippocampus is prominent in the cuprizone model.

Koutsoudaki PN, Skripuletz T, Gudi V, Moharregh-Khiabani D, Hildebrandt H, Trebst C, Stangel M.

Neurosci Lett. 2009 Feb 13;451(1):83-8. doi: 10.1016/j.neulet.2008.11.058. Epub 2008 Dec 3.

PMID:
19084049
49.

CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions.

Trebst C, König F, Ransohoff R, Brück W, Stangel M.

Mult Scler. 2008 Jul;14(6):728-33. doi: 10.1177/1352458508089359.

PMID:
18611987
50.

The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination.

Lindner M, Trebst C, Heine S, Skripuletz T, Koutsoudaki PN, Stangel M.

Glia. 2008 Aug 1;56(10):1104-13. doi: 10.1002/glia.20682. Erratum in: Glia. 2009 Mar;57(4):465.

PMID:
18442092

Supplemental Content

Loading ...
Support Center